[HTML][HTML] All-case Japanese post-marketing surveillance of the real-world safety and efficacy of rituximab treatment in patients with refractory nephrotic syndrome
M Kobayashi, Y Kageyama, T Ando… - Clinical and …, 2021 - Springer
Background Rituximab is conditionally approved in Japan for use in patients with refractory
nephrotic syndrome. To meet the conditions of approval, an all-case post-marketing …
nephrotic syndrome. To meet the conditions of approval, an all-case post-marketing …
All-case Japanese post-marketing surveillance of the real-world safety and efficacy of rituximab treatment in patients with refractory nephrotic syndrome
M Kobayashi, Y Kageyama, T Ando… - Clinical and …, 2021 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: sec>< jats: title> Background</jats: title>< jats: p>
Rituximab is conditionally approved in Japan for use in patients with refractory nephrotic …
Rituximab is conditionally approved in Japan for use in patients with refractory nephrotic …
All-case Japanese post-marketing surveillance of the real-world safety and efficacy of rituximab treatment in patients with refractory nephrotic syndrome.
M Kobayashi, Y Kageyama, T Ando… - Clinical and …, 2021 - europepmc.org
Background Rituximab is conditionally approved in Japan for use in patients with refractory
nephrotic syndrome. To meet the conditions of approval, an all-case post-marketing …
nephrotic syndrome. To meet the conditions of approval, an all-case post-marketing …
All-case Japanese post-marketing surveillance of the real-world safety and efficacy of rituximab treatment in patients with refractory nephrotic syndrome
K Mana, K Yutaro, A Takashi… - Clinical and …, 2021 - search.proquest.com
Background Rituximab is conditionally approved in Japan for use in patients with refractory
nephrotic syndrome. To meet the conditions of approval, an all-case post-marketing …
nephrotic syndrome. To meet the conditions of approval, an all-case post-marketing …
All-case Japanese post-marketing surveillance of the real-world safety and efficacy of rituximab treatment in patients with refractory nephrotic syndrome
M Kobayashi, Y Kageyama, T Ando… - Clinical and …, 2021 - hero.epa.gov
BACKGROUND: Rituximab is conditionally approved in Japan for use in patients with
refractory nephrotic syndrome. To meet the conditions of approval, an all-case post …
refractory nephrotic syndrome. To meet the conditions of approval, an all-case post …
All-case Japanese post-marketing surveillance of the real-world safety and efficacy of rituximab treatment in patients with refractory nephrotic syndrome.
M Kobayashi, Y Kageyama, T Ando… - Clinical & …, 2021 - search.ebscohost.com
Background: Rituximab is conditionally approved in Japan for use in patients with refractory
nephrotic syndrome. To meet the conditions of approval, an all-case post-marketing …
nephrotic syndrome. To meet the conditions of approval, an all-case post-marketing …
All-case Japanese post-marketing surveillance of the real-world safety and efficacy of rituximab treatment in patients with refractory nephrotic syndrome
M Kobayashi, Y Kageyama, T Ando… - Clinical and …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Rituximab is conditionally approved in Japan for use in patients with refractory
nephrotic syndrome. To meet the conditions of approval, an all-case post-marketing …
nephrotic syndrome. To meet the conditions of approval, an all-case post-marketing …
[HTML][HTML] All-case Japanese post-marketing surveillance of the real-world safety and efficacy of rituximab treatment in patients with refractory nephrotic syndrome
M Kobayashi, Y Kageyama, T Ando… - Clinical and …, 2021 - ncbi.nlm.nih.gov
Background Rituximab is conditionally approved in Japan for use in patients with refractory
nephrotic syndrome. To meet the conditions of approval, an all-case post-marketing …
nephrotic syndrome. To meet the conditions of approval, an all-case post-marketing …